{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 67,
  "pageCount": 132,
  "prevPage": 66,
  "nextPage": 68,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "The chart is a swimmer plot (a type of timeline/bar chart used in oncology clinical trials).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/67",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-67",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Swimmer plot of patient treatment duration and response",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "064428c4-32e0-4075-a8ff-ae6f2520c6b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "CPI = Checkpoint Inhibitors, IV=Intravenous, PD=Progressive Disease, PR=Partial Response, RP2D=Recommended Phase 2 Dose, SD=Stable Disease. Data cut off March 15, 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc53c021-b3d4-4932-b472-157734b4672e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.45,
        "y": 0.65
      },
      "kind": "legend",
      "text": "Evaluation of SD, PD, PR, Ongoing, Rollover to combo",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66bd82c4-e0fe-43a3-ba44-070f4069a833",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.675,
        "y": 0.33
      },
      "kind": "list",
      "text": "Preliminary data (ongoing study): Out of 28 evaluable patients (with >= 1 scans): Total 3 responses observed, with tumor shrinkage (2 mucosal, 1 cutaneous). Majority of patients are ongoing as of March 15, 2021.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d8932d4-579f-4a9f-9bb4-65000149a0b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "ARTISTRY-1: Nemvaleukin Monotherapy Responses in CPI-Experienced Melanoma Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e985943-f60a-417e-9691-36efbe9080c4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Small Multiples",
      "slug": "small-multiples",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "82963c4b-c13c-4a4e-8a1c-cd87f1c4f0a4",
      "evidence": "Swimmer plot of patient treatment duration and response",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}